Key facts
- This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2023, 15:27.
Peter Greenleaf - 02 Mar 2023 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- AUPH
- Reported as of
- 02 Mar 2023
- Net transaction value
- -$292,785
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2023, 15:27:56 UTC
- Prior SEC filing
- 26 May 2022
- Next SEC filing
- 22 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter S. Greenleaf
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 06 Mar 2023.
Change
- Previous filing in this sequence was filed on 26 May 2022.
- Current net transaction value: -$292,785.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Award
- Transaction value
- Shares
- +667,407
- Change %
- +192%
- Price
- Shares after
- 1,015,718
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
AUPH
transaction
Common Stock
Sale
- Transaction value
- $292,785
- Shares
- -32,750
- Change %
- -3.2%
- Price
- $8.94
- Shares after
- 982,968
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date.
Footnote F2
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,221 shares of common stock were acquired on May 31, 2022 and 1,883 shares of common stock were acquired on November 30, 2022.
Footnote F4
The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 667,407 newly awarded RSUs, 312,240 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 32,967 shares of common stock. On March 2, 2023, 104,080 of Prior RSUs vested and 208,160 of Prior RSUs remained unvested.
Footnote F5
Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.